-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzinova plans interim analysis of Alzheimer's vaccine trial in third quarter of 2028

PUBT·11/19/2026 07:54:08
Listen to the news
Alzinova plans interim analysis of Alzheimer's vaccine trial in third quarter of 2028
  • Alzinova plans a blinded interim review and separate futility analysis for ADVANCE, its Phase 2a trial of ALZ-101 in early Alzheimer's disease.
  • Interim findings are expected around the third quarter of 2028, subject to enrollment and study progress; final results are anticipated in late 2029.
  • The blinded review will assess early biological and clinical effects without revealing treatment assignments.
  • Independent statisticians will assess whether the trial is unlikely to succeed; a stopping recommendation would not require termination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.